A Phase I/II, Open-Label, Multicentre 2-Part Study to Assess the Safety, Tolerability, Pharmacokinetics, and Efficacy of AZD2811 Nanoparticle in Patients With Relapsed Acute Myeloid Leukaemia/High-Risk Myelodysplastic Syndrome or Treatment-Naïve Patients Not Eligible for Intensive Induction Therapy.

Trial Profile

A Phase I/II, Open-Label, Multicentre 2-Part Study to Assess the Safety, Tolerability, Pharmacokinetics, and Efficacy of AZD2811 Nanoparticle in Patients With Relapsed Acute Myeloid Leukaemia/High-Risk Myelodysplastic Syndrome or Treatment-Naïve Patients Not Eligible for Intensive Induction Therapy.

Recruiting
Phase of Trial: Phase I/II

Latest Information Update: 14 Sep 2017

At a glance

  • Drugs AZD 2811 (Primary)
  • Indications Acute myeloid leukaemia; Myelodysplastic syndromes
  • Focus Adverse reactions; Therapeutic Use
  • Sponsors AstraZeneca
  • Most Recent Events

    • 11 Sep 2017 Planned End Date changed from 4 Dec 2019 to 5 Dec 2019.
    • 11 Sep 2017 Planned primary completion date changed from 4 Dec 2019 to 5 Dec 2019.
    • 11 Sep 2017 Status changed from not yet recruiting to recruiting.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top